

Optimal sequencing of enzalutamide and abiraterone ac castration-resistant prostate cancer: a multicentre, ran crossover trial

Lancet Oncology, The
20, 1730-1739

DOI: 10.1016/s1470-2045(19)30688-6

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Androgen receptor-targeted agents in the management of advanced prostate cancer. <i>Lancet Oncology</i> , 2019, 20, 1628-1630. | 10.7 | 1 |
| 2 | Sequence of AR inhibitors affects outcome. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 69-69. | 27.6 | 5 |
| 3 | A high neutrophil-to-lymphocyte ratio is a poor prognostic factor for castration-resistant prostate cancer patients who undergo abiraterone acetate or enzalutamide treatment. <i>BMC Cancer</i> , 2020, 20, 919. | 2.6 | 12 |
| 4 | Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer. <i>PLoS ONE</i> , 2020, 15, e0239686. | 2.5 | 6 |
| 5 | Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 24, 100193. | 1.7 | 2 |
| 6 | Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8277. | 4.1 | 14 |
| 7 | A Phase Ib/Ila Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5338-5347. | 7.0 | 76 |
| 8 | Effect of high-fat diet on the pharmacokinetics and safety of flumatinib in healthy Chinese subjects. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 339-346. | 2.3 | 4 |
| 9 | Systematic Review and Meta-Analysis of Correlation of Progression-Free Survival-2 and Overall Survival in Solid Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 1349. | 2.8 | 22 |
| 10 | RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28092-28101. | 7.1 | 20 |
| 11 | Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. <i>Cancer Cell</i> , 2020, 38, 489-499.e3. | 16.8 | 216 |
| 12 | Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. <i>Clinical Cancer Research</i> , 2020, 26, 6122-6131. | 7.0 | 9 |
| 13 | Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357. | 27.0 | 440 |
| 15 | YB-1 variant and androgen receptor axis-targeted agents in metastatic castration-resistant prostate cancer patients. <i>Pharmacogenomics</i> , 2020, 21, 919-928. | 1.3 | 3 |
| 16 | Management of Advanced Prostate Cancer in Clinical Practice: Real-World Answers to Challenging Dilemmas. <i>JCO Oncology Practice</i> , 2020, 16, 783-789. | 2.9 | 6 |
| 18 | Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1285-1301. | 3.0 | 42 |
| 19 | Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. <i>Nature Communications</i> , 2020, 11, 5549. | 12.8 | 76 |
| 20 | <p><Metastatic Hormone-sensitive Prostate Cancer:ÂCurrent Perspective on the Evolving Therapeutic Landscape</p></p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3571-3581. | 2.0 | 23 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 21 | Pharmacotherapeutic strategies for castrate-resistant prostate cancer. Expert Opinion on Pharmacotherapy, 2020, 21, 1431-1448. | 1.8 | 23 |
| 22 | Novel therapies for advanced urologic cancers. Current Opinion in Urology, 2020, 30, 594-601. | 1.8 | 2 |
| 23 | Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends in Cancer, 2020, 6, 702-715. | 7.4 | 122 |
| 24 | Abiraterone acetate plus Prednisone/Prednisolone compared with Enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES). BJUI Compass, 2020, 1, 21-31. | 1.3 | 1 |
| 25 | Living Longer and Better with Advanced Prostate Cancer. European Urology, 2020, 78, 358-359. | 1.9 | 0 |
| 26 | The role of taxane-based chemotherapy in the treatment of prostate cancer. Current Opinion in Urology, 2020, 30, 527-533. | 1.8 | 5 |
| 27 | Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy. Expert Review of Anticancer Therapy, 2020, 20, 629-638. | 2.4 | 4 |
| 28 | Androgen receptor variant-driven prostate cancer II: advances in laboratory investigations. Prostate Cancer and Prostatic Diseases, 2020, 23, 381-397. | 3.9 | 34 |
| 29 | Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2020, 23, 539-548. | 3.9 | 27 |
| 30 | HSD3B1 (1245A>C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide: results from two prospective studies. Annals of Oncology, 2020, 31, 1186-1197. | 1.2 | 26 |
| 31 | Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2020, 31, 1119-1134. | 1.2 | 485 |
| 32 | Re: Olaparib for Metastatic Castration-resistant Prostate Cancer. European Urology, 2020, 78, 767-768. | 1.9 | 2 |
| 34 | Does sequencing order of antiandrogens in prostate cancer matter?. Nature Reviews Urology, 2020, 17, 197-198. | 3.8 | 3 |
| 35 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547. | 1.9 | 278 |
| 37 | Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?. European Urology Focus, 2021, 7, 752-763. | 3.1 | 9 |
| 38 | Recent progress in treating advanced prostate cancer. Current Opinion in Oncology, 2020, 32, 210-215. | 2.4 | 26 |
| 40 | Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients. Supportive Care in Cancer, 2021, 29, 917-923. | 2.2 | 2 |
| 41 | The Impact of Treatment Crossover and Prostate-specific Antigen Flare with Enzalutamide and Abiraterone in Metastatic Castrate Resistant Prostate Cancer. Clinical Oncology, 2021, 33, e92. | 1.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 42 | Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 170-172. | 1.9 | 3 |
| 43 | Management of men with metastatic castration-resistant prostate cancer following potent androgen receptor inhibition: a review of novel investigational therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 301-309. | 3.9 | 19 |
| 45 | Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 149-163. | 2.4 | 4 |
| 46 | Overall Survival Among Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancer Under Abiraterone Versus Enzalutamide: A Direct Comparison Based on a 2014–2018 French Population Study (the SPEAR Cohort). <i>American Journal of Epidemiology</i> , 2021, 190, 413-422. | 3.4 | 16 |
| 47 | Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3918-3930. | 1.4 | 10 |
| 48 | Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3931-3945. | 1.4 | 3 |
| 49 | <i>BRCA2</i> , <i>ATM</i> , and <i>CDK12</i> Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression. <i>Clinical Cancer Research</i> , 2021, 27, 1650-1662. | 7.0 | 52 |
| 50 | Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. <i>Journal of Urology</i> , 2021, 205, 14-21. | 0.4 | 167 |
| 51 | Clinical implications of genomic alterations in metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 310-322. | 3.9 | 12 |
| 52 | Survival outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1032-1040. | 3.9 | 28 |
| 53 | Optimal treatment sequencing of abiraterone acetate plus prednisone and enzalutamide in patients with castration-resistant metastatic prostate cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102152. | 7.7 | 10 |
| 54 | The Real-World Experience of Single-Center, Retrospective Study of the Prognostic Effect of Secondary Hormone Agent on Survival in Patients With Hormone-Refractory Metastatic Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2021, 19, 48-59. | 0.1 | 0 |
| 55 | Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973. | 4.1 | 15 |
| 56 | Resistance to second-generation androgen receptor antagonists in prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 209-226. | 3.8 | 59 |
| 57 | Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 634-640. | 0.7 | 3 |
| 58 | Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naïve disease. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1287-1297. | 1.3 | 1 |
| 59 | Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 1174-1176. | 27.0 | 1 |
| 60 | Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. <i>Cancer Science</i> , 2021, 112, 1899-1910. | 3.9 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 61 | Highlighting recent treatment advances in metastatic prostate cancer: expanding the treatment arsenal. <i>Current Opinion in Oncology</i> , 2021, 33, 252-256. | 2.4 | 3 |
| 63 | Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 948-961. | 3.9 | 5 |
| 64 | Endocrine therapy for cancer. <i>Surgery</i> , 2021, 39, 208-214. | 0.3 | 0 |
| 65 | Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1625-1632. | 1.8 | 5 |
| 66 | TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 1371-1382. | 1.6 | 65 |
| 67 | Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. <i>Clinical Cancer Research</i> , 2021, 27, 3610-3619. | 7.0 | 17 |
| 68 | An up-to-date evaluation of abiraterone for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1227-1234. | 1.8 | 3 |
| 69 | Resistance to the Androgen Receptor Centred Therapies: Biology and Management. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1593-1609. | 0.6 | 0 |
| 70 | Recent Advances in the Treatment of Metastatic Prostate Cancer. <i>Advances in Oncology</i> , 2021, 1, 263-272. | 0.2 | 1 |
| 71 | 2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514. | 1.7 | 5 |
| 72 | Cross-resistance and drug sequence in prostate cancer. <i>Drug Resistance Updates</i> , 2021, 56, 100761. | 14.4 | 36 |
| 73 | Olaparib vs Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2110950. | 5.9 | 4 |
| 74 | Safety and efficacy of abiraterone acetate plus prednisolone in patients with castration-resistant prostate cancer: a prospective, observational, post-marketing surveillance study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1452-1461. | 1.3 | 3 |
| 75 | Treatment-Emergent Co-Morbidities and Survival in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide. <i>Frontiers in Pharmacology</i> , 2021, 12, 669236. | 3.5 | 3 |
| 76 | Novel Treatment Strategy Using Second-Generation Androgen Receptor Inhibitors for Non-Metastatic Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 661. | 3.2 | 7 |
| 77 | Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e190-e202. | 3.8 | 9 |
| 78 | Real-World Data on Outcomes in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Abiraterone or Enzalutamide: A Regional Experience. <i>Frontiers in Oncology</i> , 2021, 11, 656146. | 2.8 | 7 |
| 79 | Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition. <i>Clinical Cancer Research</i> , 2021, 27, 4610-4623. | 7.0 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 80 | Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?. European Urology, 2021, 79, 710-712. | 1.9 | 9 |
| 81 | Olaparib for the treatment of metastatic prostate cancer. Future Oncology, 2021, 17, 2413-2429. | 2.4 | 2 |
| 82 | Outcomes of treatment choices in poor prognosis prostate cancer: not against all odds. Annals of Oncology, 2021, 32, 831-832. | 1.2 | 0 |
| 83 | Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation. Frontiers in Oncology, 2021, 11, 700543. | 2.8 | 5 |
| 84 | Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 754-763. | 1.6 | 2 |
| 85 | Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study. European Journal of Cancer, 2021, 152, 215-222. | 2.8 | 11 |
| 86 | A Prospective Study of the Relationship Between Clinical Outcomes After Enzalutamide and Serum Androgen Levels Measured via Liquid Chromatography-tandem Mass Spectrometry in Patients with Castration-resistant Prostate Cancer. European Urology Open Science, 2021, 29, 59-67. | 0.4 | 4 |
| 87 | Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial. Annals of Oncology, 2021, 32, 896-905. | 1.2 | 39 |
| 88 | Metastatic prostate cancer: clinical aspects and treatment limitations in a university hospital center in Senegal. African Journal of Urology, 2021, 27, . | 0.4 | 1 |
| 89 | A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. Annual Review of Pharmacology and Toxicology, 2022, 62, 131-153. | 9.4 | 55 |
| 90 | KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncology, 2021, 17, 3017-3026. | 2.4 | 19 |
| 91 | Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer. Cancer Medicine, 2021, 10, 6304-6309. | 2.8 | 3 |
| 93 | A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer. Cancer Medicine, 2021, 10, 6354-6364. | 2.8 | 7 |
| 94 | Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers, 2021, 13, 4951. | 3.7 | 19 |
| 95 | Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 4.e19-4.e28. | 1.6 | 7 |
| 96 | Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2021, 22, 1541-1559. | 10.7 | 60 |
| 97 | Activity of New Synthetic (2-Chloroethylthio)-1,4-naphthoquinones in Prostate Cancer Cells. Pharmaceuticals, 2021, 14, 949. | 3.8 | 6 |
| 98 | Optimal Sequencing and Predictive Biomarkers in Patients with Advanced Prostate Cancer. Cancers, 2021, 13, 4522. | 3.7 | 22 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 99 | Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2022, 7, 100808. | 1.2 | 4 |
| 100 | Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55. | 2.9 | 75 |
| 101 | Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090. | 13.7 | 240 |
| 102 | Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients. <i>ESMO Open</i> , 2021, 6, 100261. | 4.5 | 14 |
| 103 | Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study. <i>European Urology</i> , 2021, 80, 497-506. | 1.9 | 16 |
| 104 | Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e326-e333. | 1.9 | 7 |
| 105 | The treatment landscape of metastatic prostate cancer. <i>Cancer Letters</i> , 2021, 519, 20-29. | 7.2 | 50 |
| 106 | Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD Study. <i>ESMO Open</i> , 2021, 6, 100241. | 4.5 | 13 |
| 108 | Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844. | 1.9 | 47 |
| 111 | A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 13247-13263. | 2.0 | 8 |
| 112 | Docetaxel Rechallenge Improves Survival in Patients With Metastatic Castration-resistant Prostate Cancer: A Retrospective Study. <i>In Vivo</i> , 2021, 35, 3509-3519. | 1.3 | 5 |
| 113 | Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45. | 2.4 | 4 |
| 114 | Prostatakarzinom: Die optimale Sequenz für die zweite und nachfolgende Therapielinien beim mCRPC ist noch nicht gefunden. <i>Karger Kompass Onkologie</i> , 2020, 7, 197-198. | 0.0 | 0 |
| 115 | Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer. <i>Prostate International</i> , 2021, 10, 50-55. | 2.3 | 3 |
| 116 | Anticipating the Next Challenging Clinical Dilemmas in Prostate Cancer. <i>JCO Oncology Practice</i> , 2020, 16, 791-792. | 2.9 | 0 |
| 120 | Round up. <i>Indian Journal of Urology</i> , 2020, 36, 6-7. | 0.6 | 0 |
| 121 | Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer-a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3188-3198. | 1.4 | 1 |
| 122 | Abiraterone acetate – 10 clinically relevant facts. <i>OnCOReview</i> , 2021, 11, 80-84. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 123 | Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis. International Journal of Clinical Oncology, 2022, 27, 592-601. | 2.2 | 7 |
| 124 | Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies. Current Oncology, 2021, 28, 4894-4928. | 2.2 | 0 |
| 125 | Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. Canadian Urological Association Journal, 2021, 16, . | 0.6 | 2 |
| 126 | Progress in Clinical Application of Abiraterone in the Treatment of mCRPC. Advances in Clinical Medicine, 2021, 11, 5507-5513. | 0.0 | 0 |
| 127 | The prostate cancer landscape in Europe: Current challenges, future opportunities. Cancer Letters, 2022, 526, 304-310. | 7.2 | 16 |
| 128 | Prostatakarzinom: Kein harmloser Alterskrebs. , 0, , . | | 1 |
| 129 | Rapidly evolving treatment paradigm and considerations for sequencing therapies in metastatic prostate cancer—a narrative review. Translational Andrology and Urology, 2021, 10, 3188-3198. | 1.4 | 3 |
| 130 | Metastatic Prostate Cancer: Treatment Options. Oncology, 2022, 100, 48-59. | 1.9 | 47 |
| 131 | Real-world first-line systemic therapy patterns in metastatic castration-resistant prostate cancer. BJU International, 2022, 3, 205-213. | 1.3 | 6 |
| 132 | Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors. JMA Journal, 2022, 5, 83-90. | 0.8 | 1 |
| 133 | Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD. Prostate Cancer and Prostatic Diseases, 2023, 26, 67-73. | 3.9 | 2 |
| 134 | Rational Second-Generation Antiandrogen Use in Prostate Cancer. Oncologist, 0, , . | 3.7 | 10 |
| 135 | Should Early Use of Chemotherapy Be Avoided in the Treatment of Metastatic Prostate Cancer?. JMA Journal, 2022, 5, 91-92. | 0.8 | 0 |
| 136 | Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus. Oncology and Therapy, 2022, 10, 143-165. | 2.6 | 1 |
| 137 | Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems. Frontiers in Pharmacology, 2022, 13, 839620. | 3.5 | 4 |
| 138 | Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?. Cancers, 2022, 14, 801. | 3.7 | 23 |
| 139 | Managing advanced prostate cancer in the Asia Pacific region: “Real-world” application of Advanced Prostate Cancer Consensus Conference 2019 statements. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 686-695. | 1.1 | 5 |
| 140 | PARP inhibitors for metastatic castration-resistant prostate cancer: Biological rationale and current evidence. Cancer Treatment Reviews, 2022, 104, 102359. | 7.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 141 | Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 192.e1-192.e9. | 1.6 | 6 |
| 142 | Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 306-313. | 3.9 | 5 |
| 143 | Controlling the Control Arm in Metastatic Castration-Resistant Prostate Cancer Trials: Best Standard of Care or the Minimum Standard of Care?. <i>Journal of Clinical Oncology</i> , 2022, 40, 1518-1521. | 1.6 | 9 |
| 144 | Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?. <i>Frontiers in Pharmacology</i> , 2022, 13, 843110. | 3.5 | 3 |
| 145 | Mismatch repair deficiency and clinical implications in prostate cancer. <i>Prostate</i> , 2022, 82, . | 2.3 | 9 |
| 146 | Targeting the androgen receptor signaling pathway in advanced prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1224-1235. | 1.0 | 5 |
| 147 | Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study. <i>Archivio Italiano Di Urologia Andrologia</i> , 2021, 93, 393-398. | 0.8 | 4 |
| 149 | Real-world cabazitaxel use and outcomes in metastatic castrate-resistant prostate cancer: the impact of response to first ARPI. <i>Clinical Genitourinary Cancer</i> , 2022, , . | 1.9 | 0 |
| 150 | Assessment and Management of Cognitive Function in Patients with Prostate Cancer Treated with Second-Generation Androgen Receptor Pathway Inhibitors. <i>CNS Drugs</i> , 2022, 36, 419-449. | 5.9 | 6 |
| 151 | Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management. <i>Current Opinion in Urology</i> , 2022, 32, 283-291. | 1.8 | 4 |
| 152 | Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. , 2022, 39, 107. | | 2 |
| 154 | Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial. <i>European Urology Open Science</i> , 2022, 41, 16-23. | 0.4 | 3 |
| 155 | Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease. <i>Anticancer Research</i> , 2022, 42, 3041-3047. | 1.1 | 1 |
| 156 | Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. <i>Prostate</i> , 2022, 82, . | 2.3 | 6 |
| 157 | Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue. <i>Frontiers in Oncology</i> , 0, 12, . | 2.8 | 8 |
| 158 | Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, . | 17.1 | 40 |
| 159 | Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, . | 0.0 | 0 |
| 160 | Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis—Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. <i>European Urology Focus</i> , 2023, 9, 106-109. | 3.1 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 161 | Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer. <i>Nature</i> , 2022, 608, 199-208. | 27.8 | 63 |
| 162 | Second generation androgen receptor antagonists and challenges in prostate cancer treatment. <i>Cell Death and Disease</i> , 2022, 13, . | 6.3 | 32 |
| 163 | Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic. <i>American Journal of Men's Health</i> , 2022, 16, 155798832211155. | 1.6 | 1 |
| 164 | Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience. <i>PLoS ONE</i> , 2022, 17, e0264800. | 2.5 | 1 |
| 165 | Should We “PROpel” Olaparib Forward for Metastatic Castration-Resistant Prostate Cancer?. , 2022, 1, . | | 0 |
| 166 | m6A Methylation Regulators Are Predictive Biomarkers for Tumour Metastasis in Prostate Cancer. <i>Cancers</i> , 2022, 14, 4035. | 3.7 | 5 |
| 167 | Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry. <i>European Urology Open Science</i> , 2022, 45, 12-22. | 0.4 | 2 |
| 168 | Impacts of androgen deprivation therapy on the risks and outcomes of SARS-CoV-2 infection in patients with prostate cancer. <i>Asian Journal of Andrology</i> , 2023, 25, 366-374. | 1.6 | 2 |
| 169 | Sequential therapy with darolutamide in patients with non-metastatic castration-resistant prostate cancer resistant to enzalutamide or apalutamide. <i>Cancer Medicine</i> , 0, , . | 2.8 | 1 |
| 170 | Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 743-750. | 3.9 | 7 |
| 171 | “Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil” Clinical Genitourinary Cancer, 2022, , . | 1.9 | 0 |
| 172 | Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. <i>European Urology</i> , 2023, 84, 4-6. | 1.9 | 7 |
| 173 | Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study. <i>Anticancer Research</i> , 2022, 42, 4857-4866. | 1.1 | 0 |
| 174 | The Value of Phenotypic Precision Medicine in Prostate Cancer. <i>Oncologist</i> , 2023, 28, 93-104. | 3.7 | 5 |
| 176 | Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. <i>Frontiers in Endocrinology</i> , 0, 13, . | 3.5 | 7 |
| 177 | Naphthoquinones and derivatives as potential anticancer agents: An updated review. <i>Chemico-Biological Interactions</i> , 2022, 368, 110198. | 4.0 | 24 |
| 178 | A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 8.2 | 3 |
| 179 | Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1163-1175. | 2.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 180 | The evolving landscape of PARP inhibitors in castration-resistant prostate cancer: a spotlight on treatment combinations. Expert Review of Clinical Pharmacology, 2022, 15, 1293-1304. | 3.1 | 0 |
| 181 | French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. Progres En Urologie, 2022, 32, 1373-1419. | 0.8 | 5 |
| 182 | Risk of cognitive impairment in men with advanced prostate cancer treated with NHAs: A systematic review and network meta-analysis. Clinical and Translational Science, 2023, 16, 313-325. | 3.1 | 3 |
| 183 | Objective response rate of placebo in randomized controlled trials of anticancer medicines. EClinicalMedicine, 2023, 55, 101753. | 7.1 | 4 |
| 185 | Clinical Outcomes of First Subsequent Therapies After Abiraterone Acetate Plus Prednisone for High-Risk Metastatic Castration-Sensitive Prostate Cancer in the LATITUDE Study. Targeted Oncology, 0, , . | 3.6 | 0 |
| 186 | Therapeutic sensitivity to standard treatments in BRCA positive metastatic castration-resistant prostate cancer patients—a systematic review and meta-analysis. Prostate Cancer and Prostatic Diseases, 2023, 26, 665-672. | 3.9 | 6 |
| 187 | Plasma progastrin-releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis-targeted agents in patients with metastatic castration-resistant prostate cancer. Cancer Reports, 0, , . | 1.4 | 1 |
| 188 | Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors. Cancer Science, 2023, 114, 1625-1634. | 3.9 | 2 |
| 189 | Prevalence and Causes of Discontinuation of Androgen Receptor Inhibitors in Advanced Prostate Cancer Patients and Analysis of Physician Management to Increase Duration of Therapy. Urology, 2023, 173, 142-148. | 1.0 | 1 |
| 190 | Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. World Journal of Men's Health, 2023, 41, 769. | 3.3 | 10 |
| 191 | Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16). Journal of Clinical Oncology, 2023, 41, 3608-3615. | 1.6 | 2 |
| 192 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2023, 41, 3339-3351. | 1.6 | 60 |
| 193 | Re: Darolutamide and Survival in Metastatic, Hormone-sensitive Prostate Cancer. European Urology, 2023, 83, 584-585. | 1.9 | 0 |
| 194 | Taxanes Versus Androgen Receptor Therapy as Second-Line Treatment for Castrate-Resistant Metastatic Prostate Cancer After First-Line Androgen Receptor Therapy. Clinical Genitourinary Cancer, 2023, 21, 349-356.e2. | 1.9 | 1 |
| 195 | Re: Continuous Enzalutamide After Progression of Metastatic Castration-resistant Prostate Cancer Treated with Docetaxel (PRESIDE): An International, Randomised, Phase 3b Study. European Urology, 2023, , . | 1.9 | 0 |
| 197 | How to Optimally Sequence Available Therapy Lines in Advanced Prostate Cancer. Acta Clinica Croatica, 2022, , . | 0.2 | 0 |
| 198 | Utilization of Next-Generation Sequencing in Conjunction With Immunohistochemistry to Predict Exceptional Response to Combination Immune Checkpoint Therapy in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2023, , . | 3.0 | 1 |
| 199 | Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study. Oncologist, 2023, 28, e737-e747. | 3.7 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 200 | Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol. <i>Lancet Oncology</i> , The, 2023, 24, 443-456. | 10.7 | 12 |
| 201 | Frailty and survival among veterans treated with abiraterone or enzalutamide for metastatic castration-resistant prostate cancer. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101520. | 1.0 | 1 |
| 202 | Reply to E. Hindi. <i>Journal of Clinical Oncology</i> , 0, , . | 1.6 | 0 |
| 203 | Histone H2A Lys130 acetylation epigenetically regulates androgen production in prostate cancer. <i>Nature Communications</i> , 2023, 14, . | 12.8 | 7 |
| 204 | Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan. <i>BMC Cancer</i> , 2023, 23, . | 2.6 | 0 |
| 205 | Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study. <i>Prostate</i> , 2023, 83, 1279-1284. | 2.3 | 1 |
| 208 | A-Review on Anticancer Agents: Conventional Drugs and Novel Target Specific Inhibitors. <i>Oriental Journal of Chemistry</i> , 2023, 39, 657-669. | 0.3 | 0 |
| 209 | Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2023, 29, 758-768. | 0.9 | 0 |
| 210 | Targeting the Androgen Signaling Axis in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2023, 41, 4267-4278. | 1.6 | 12 |
| 211 | Advances in the treatment of metastatic prostate cancer. <i>Trends in Cancer</i> , 2023, 9, 840-854. | 7.4 | 7 |
| 212 | Ozone attenuates chemotherapy-induced peripheral neuropathy via upregulating the AMPK-SOCS3 axis. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 1031-1039. | 0.9 | 1 |
| 213 | [¹⁷⁷ Lu]-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial. <i>Journal of Nuclear Medicine</i> , 0, , jnumed.123.266141. | 5.0 | 1 |
| 214 | Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2023, 12, 19414-19422. | 2.8 | 0 |
| 215 | Metastasiertes kastrationsresistentes Prostatakarzinom mit Therapiesequenz (mCRPC). , 2023, , 77-92. | | 0 |
| 216 | Therapy With Metronomic Cyclophosphamide (mCyc) for Previously-Treated Metastatic Castrate-Resistant Prostate Cancer (mCRPC). <i>Clinical Genitourinary Cancer</i> , 2024, 22, 217-223. | 1.9 | 0 |
| 217 | Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study. <i>European Urology Oncology</i> , 2023, , . | 5.4 | 0 |
| 218 | Stereotactic body radiation therapy to postpone systemic therapy escalation for castration-resistant prostate cancer: A multicenter retrospective analysis. <i>Clinical and Translational Radiation Oncology</i> , 2024, 45, 100710. | 1.7 | 0 |
| 219 | Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis. <i>International Journal of Clinical Oncology</i> , 2024, 29, 213-221. | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 220 | Novel signatures of prostate cancer progression and therapeutic resistance. Expert Opinion on Therapeutic Targets, 2023, 27, 1195-1206. | 3.4 | 0 |
| 221 | Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clinical Cancer Research, 2024, 30, 1111-1120. | 7.0 | 0 |
| 222 | Development of PARP inhibitors in advanced prostate cancer. Therapeutic Advances in Medical Oncology, 2024, 16, . | 3.2 | 1 |
| 223 | Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa. Cancers, 2024, 16, 508. | 3.7 | 0 |
| 224 | Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis. Critical Reviews in Oncology/Hematology, 2024, 196, 104286. | 4.4 | 0 |
| 225 | Malignome des Urogenitaltrakts. , 2024, , 801-864. | | 0 |
| 226 | Prediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer. Nature Communications, 2024, 15, . | 12.8 | 0 |
| 227 | A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?. Critical Reviews in Oncology/Hematology, 2024, 196, 104273. | 4.4 | 0 |